NCT03094052 2025-06-26Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibUniversity of California, San FranciscoPhase 2 Completed11 enrolled 12 charts
NCT05252988 2025-04-01DIANERSpanish Breast Cancer Research GroupPhase 2 Active not recruiting177 enrolled
NCT04366713 2023-02-10A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibPuma Biotechnology, Inc.Phase 2 Completed6 enrolled 8 charts
NCT02400476 2022-05-06An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamidePuma Biotechnology, Inc.Phase 2 Completed563 enrolled 16 charts